HUI EVANA YEE WAH 4

What Happened
Director Hui Evana Yee Wah disposed of 19,000 derivative securities (options) back to Regencell Bioscience Holdings Ltd. The issuer repurchased the options on May 27, 2026 at a stated price of $15.00 per option. This filing reports a disposition of options (a sale/repurchase), not a purchase of shares.

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 29, 2026 (timely within the required window).
• Instrument: Options to purchase 19,000 ordinary shares (derivative transaction).
• Repurchase price: $15.00 per option (gross = $285,000), but the aggregate consideration payable to the reporting person is reduced by the aggregate exercise price of the repurchased options (see footnote).
• Footnote F1: Exercise price has been adjusted for any share splits since grant.
• Footnote F2: Issuer repurchased the 19,000 options at $15.00 each; the cash paid to the reporting person is further reduced by the total exercise price of those options.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context
This was a derivative disposition (issuer repurchase of options) rather than an open-market sale of shares or an option exercise-for-stock. Repurchases like this typically reflect a contractual agreement between the insider and the company and should not be read as a direct buy/sell signal of share ownership intent. The filing appears timely (reported two days after the transaction).